# Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy

> **NCT05673850** · — · COMPLETED · sponsor: **Peking University** · enrollment: 518 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** NET or NCT

## Key facts

- **NCT ID:** NCT05673850
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-01
- **Primary completion:** 2022-08-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 518 (ACTUAL)
- **Last updated:** 2023-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05673850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05673850, "Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05673850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*